

## REMARKS


The title has been amended and a paragraph cross-referencing related applications has been added. The paragraph starting at page 8, line 12 has been amended to recite a corrected final page number for the reference cited. This amendment corrects a typographical error that is obvious if one refers to the actual page numbers of the cited reference. The paragraph starting at page 16, line 10 has been amended to remove references to Orthomyxoviridae, Bunyaviridae, and Arenaviridae. This amendment is based on the known fact that viruses belonging to Orthomyxoviridae, Bunyaviridae, and Arenaviridae are minus-strand RNA viruses, but not single-stranded minus-strand RNA viruses. The paragraph starting at page 29, line 14 has been amended to recite “a T7 RNA polymerase-expressing plasmid (for example, 0.5μg)”; “pCAGGS-T7 for example, 0.5μg”; “pSeV(TDK)18+GFP”; and “(pSeV/ΔF-GFP).” Support for this amendment is found, for example, on page 12, lines 13-16, and Example 5 (particularly, page 43, lines 13-15, and page 43, line 36 to page 44, line 2) of the specification as filed. Finally, applicants include a sequence listing, based on the sequence listing as filed with WIPO, in which the bibliographic and priority information has been updated. No new matter has been added by the present amendment.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 17 July 2006

  
\_\_\_\_\_  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045